Abstract
Patients with resectable squamous cell carcinoma were randomly allocated after surgery to receive either no further treatment (57 patients) or a single intrapleural injection of BCG (61 patients). No significant improvement in survival was observed in patients treated with BCG, even when their disease was staged as N0. These was a slight trend for the recurrence rate to be lower in patients classed as N0, but this was not significant.
Keywords: Carcinoma, Cell Carcinoma, Cancer Research, Squamous Cell Carcinoma, Squamous Cell
References
- 1.Jansen HM, The TH, Orie NGM. Adjuvant immunotherapy with BCG in squamous cell bronchial carcinoma. Thorax. 1980;35:781–787. doi: 10.1136/thx.35.10.781. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Lowe J, Iles PB, Shore DF, Langmann MJS, Baldwin RW. Intrapleural BCG in operable lung cancer. Lancet. 1980;1:11–14. doi: 10.1016/s0140-6736(80)90551-6. [DOI] [PubMed] [Google Scholar]
- 3.McKneally MF, Maver C, Kausel HW, Alley RD. Regional immunotherapy with intrapleural BCG for lung cancer. J Thorac Cardiovasc Surg. 1976;72:333–338. [PubMed] [Google Scholar]
- 4.Renault P. Valeur prognostique des structures. Le code T.N.M. Rev Fr Mal Respir. 1977;5(2):45–58. [Google Scholar]
- 5.Wright PW, Hill LD, Peterson AV, Pinkham R, Johnson L, Ivey T, Bernstein I, Bagley C, Anderson R. Preliminary results of combined surgery and adjuvant bacillus Calmette-Guérin plus levamisole treatment of resectable lung cancer. Cancer Treat Rep. 1978;62:1671–1675. [PubMed] [Google Scholar]